These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 29579339)

  • 1. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
    J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Tepper J; Qaqish B; Green R; Aumer SL; Hayes N; Weiss J; Grilley-Olson J; Zanation A; Hackman T; Funkhouser W; Sheets N; Weissler M; Mendenhall W
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):976-85. PubMed ID: 26581135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
    Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
    Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
    Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
    Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
    J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
    Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
    Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    Yom SS; Torres-Saavedra P; Caudell JJ; Waldron JN; Gillison ML; Xia P; Truong MT; Kong C; Jordan R; Subramaniam RM; Yao M; Chung CH; Geiger JL; Chan JW; O'Sullivan B; Blakaj DM; Mell LK; Thorstad WL; Jones CU; Banerjee RN; Lominska C; Le QT
    J Clin Oncol; 2021 Mar; 39(9):956-965. PubMed ID: 33507809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
    Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
    Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
    Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
    Hu Q; Li F; Yang K
    PeerJ; 2024; 12():e17391. PubMed ID: 38784388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
    Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
    Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
    Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
    Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
    Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P
    Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy.
    Pearlstein KA; Wang K; Amdur RJ; Shen CJ; Dagan R; Weiss J; Grilley-Olson JE; Zanation A; Hackman TG; Thorp BD; Blumberg JM; Patel S; Sheets N; Weissler MC; Mendenhall WM; Chera BS
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):646-653. PubMed ID: 30395903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer.
    Xu MJ; Plonowska KA; Gurman ZR; Humphrey AK; Ha PK; Wang SJ; El-Sayed IH; Heaton CM; George JR; Yom SS; Algazi AP; Ryan WR
    Laryngoscope; 2020 Feb; 130(2):E48-E56. PubMed ID: 30919470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.